HOME >> BIOLOGY >> NEWS
Final results demonstrate Aranesp dosed every two weeks is comparable to Epoetin alfa dosed weekly

ORLANDO, Fla., (May 15, 2005) Amgen Inc., (NASDAQ: AMGN) the world's largest biotechnology company, today announced that final results of a Phase 3 randomized, head-to-head study demonstrated that 200 mcg of Aranesp (darbepoetin alfa) administered every two weeks is as effective as 40,000 U of Epoetin alfa dosed once a week in boosting hemoglobin levels and reducing the need for red blood cell transfusions in cancer patients with chemotherapy-induced anemia. The data were presented today at the 41st Annual Meeting of the American Society of Clinical Oncology (ASCO). [Abstract #8125]

"This is the largest, randomized head-to-head comparison of darbepoetin alfa dosed every two weeks to Epoetin alfa dosed weekly, as they are most often used in current oncology practice," said John Glaspy, MD, professor, David Geffen School of Medicine, University of California at Los Angeles. "Less frequent dosing provides anemia management with less frequent injections, and for patients receiving chemotherapy every two or three weeks, less frequent office visits. Our data demonstrate that less frequent injections can be accomplished without a compromise in efficacy in terms of decreased transfusion risk or improved quality of life."

In the Phase 3 head-to-head study, a total of 1,220 patients with chemotherapy-induced anemia were randomized to receive either Aranesp 200 mcg every two weeks (n=613) or Epoetin alfa 40,000 U once a week (n=607). The majority of patients in both groups achieved the target hemoglobin of greater than or equal to 11 g/dL. Both groups of patients had similar blood transfusion rates, patient reported outcomes, and safety endpoints.

In this study, at least 90 percent of patients in both arms of the study achieved target hemoglobin of greater than or equal to 11 g/dL. Seventy-four percent of patients in the Aranesp group remained in the target range compared to 80 percent in the Epoetin alfa group. The study's primary endpoi
'"/>

Contact: Trish Hawkins
805-447-4587
Porter Novelli
16-May-2005


Page: 1 2

Related biology news :

1. Final of the 2005-06 Research Councils Business Plan Competition
2. Finally, JAP study shows headdown bedrest precisely mimics human physiology in spaceflight
3. Finally, male water fleas exposed
4. Finalists in young scholars competition announced
5. Cooperative science program yields results
6. Delayed treatment of childhood-onset bipolar disorder results in negative outcome in adults
7. Smelling for first time results from knowing abnormalities in congenital loss of smell
8. BDSI announces positive phase III clinical trial results
9. Scientists meet to review Envisat results after 5 years of operations
10. Environment and exercise may affect research results, UA study shows
11. Preliminary results of largest scan of autism DNA information

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/15/2017)... , Aug. 15 2017   ivWatch LLC , a ... intravenous (IV) therapy, today announced receipt of its ISO 13485 Certification, ... by the International Organization for Standardization (ISO®). ... ivWatch Model 400 Continuous Monitoring device for the early ... "This is an ...
(Date:7/20/2017)... (NYSE: DAL ) customers now can use fingerprints instead of ... Airport (DCA). ... Delta launches biometrics to board aircraft at Reagan Washington National Airport ... Delta,s biometric boarding pass experience that launched in May ... boarding process to allow eligible Delta SkyMiles Members who are enrolled in ...
(Date:6/30/2017)... Va. , June 30, 2017 ... leading developer and supplier of face and eye ... ATA Featured Product provider program. ... an innovative way to monitor a driver,s attentiveness ... greatly from being able to detect fatigue and ...
Breaking Biology News(10 mins):
(Date:8/15/2017)... , Aug. 15, 2017 After spending the past two ... with crowdsourced data collection, GeneFo now offers this platform to healthcare ... and amplifying support, adherence, and data collection vis a vis their ... mark the successful launch of this offer. ... GeneFo ...
(Date:8/15/2017)... ... August 15, 2017 , ... Kenall, a leader in ... to stay tightly sealed and perform efficiently for years. The downlights are ideal ... just aren't enough, such as: hospitals; behavioral health facilities; cleanrooms; containment areas; food ...
(Date:8/14/2017)... Portland, Oregon (PRWEB) , ... August 14, 2017 ... ... modules that provide essential device-to-computer interconnect using USB or PCI Express, announced the ... hardware. , SYZYGY is intended to satisfy the need for a compact, low ...
(Date:8/11/2017)... ... August 11, 2017 , ... ... and, in particular, more natural alternatives to synthetic ingredients,” said Matt Hundt, President ... Wave, with the established manufacturing presence and know-how of Biorigin will allow us ...
Breaking Biology Technology:
Cached News: